Media Newsroom of

Premark Pharma

Reinch, Baselland
Premark Pharma Licenses Worldwide Rights to PMP2207 for Ophthalmic Indications and Targets a First Regulatory Approval for Blepharitis

Premark Pharma Licenses Worldwide Rights to PMP2207 for Ophthalmic Indications and Targets a First Regulatory Approval for Blepharitis

​​​Premark Pharma announced today the completion of a licensing deal with Novartis Pharma AG, granting Premark exclusive worldwide rights to develop and commercialise PMP2207, an ophthalmic ointment formulation, as a potential treatment for blepharitis. PMP2207 is a novel ocular formulation…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login